Clinical Trials in Australia / NCT07020221
Recruiting
Phase 1/2
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221 · tracked via the Priya Life Science Australia tracker
Condition(s) studied
Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal CancerSolid Tumor, AdultG12D Mutated KRAS
Investigational drug(s) / intervention(s)
VS-7375 →Cetuximab →Carboplatin + Pemetrexed + PembrolizumabAll Carboplatin trials (590) →All Pemetrexed trials (248) →All Pembrolizumab trials (626) →Gemcitabine →Gemcitabine + Nab-paclitaxelAll Gemcitabine trials (387) →All Nab-paclitaxel trials (233) →
VS-7375: VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.
Cetuximab: Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
Carboplatin + Pemetrexed + Pembrolizumab: A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.
Gemcitabine: A chemotherapy used for the treatment of several types of cancer including advanced or metastatic pancreatic ductal adenocarcinoma.
Gemcitabine + Nab-paclitaxel: A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.
Study summary
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Eligibility
Key Inclusion Criteria:
* Individuals ≥18 years of age.
* Agreement to sign and date an informed consent form (ICF) approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
* Histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.
* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Adequate organ function
* Adequate cardiac function
* Recovered from all AEs due to previous therapies to Grade ≤1 or baseline.
* Agreement to use highly effective contraception
Key Exclusion Criteria:
* Underwent major surgical procedure as defined by the Investigator, other than for diagnosis, within 4 weeks prior to Cycle 1 Day 1,
* Receipt of chemotherapy, targeted therapy, or radiotherapy (excluding palliative radiation) within 4 weeks or 5 half-lives, whichever is shorter, or immunotherapy within 4 weeks prior to Cycle 1 Day 1
* Treatment with any investigational drug at least 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1.
* History of treatment with direct and specific KRAS G12D inhibitors.
* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.
* Inability to swallow oral medications.
* Evidence or history of uncontrolled, clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, coagulation, neurologic, dermatologic, autoimmune, or allergic disease
* Individuals who are pregnant or breastfeeding.
Primary outcome measure(s)
- Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 — Up to 2.5 years
To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 administered on a daily oral schedule in participants with advanced solid tumors harboring a KRAS G12D mutation. Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, DLTs, and dose interruptions/reductions. - Part A: To identify the MTD or MFD — Cycle 1 (each cycle is 21 days)
To identify the MTD or MFD using a BOIN design and recommend a dose for subsequent studies of VS-7375 on a daily oral schedule in participants with any KRAS G12D-mutated solid tumor. Proportion/number of participants with DLTs during the DLT assessment period (through C1D21). - Part B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen — Up to 2.5 years
To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen identified from Part A in participants with advanced KRAS G12D-mutated PDAC (cohort B1), NSCLC (cohort B2), and other solid tumors (cohort B3). Confirmed ORR, PFS rate, unconfirmed PR and CR rates, DCR, DOR, and PFS per RECIST v1.1. Overall Survival - Part C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens. — From enrollment to the end of treatment; an average of 9 months
To characterize the safety, tolerability, and AE profile of VS-7375 in the following combination regimens in participants with any solid tumor harboring a KRAS G12D mutation. * 2L+ therapy in combination with cetuximab in participants with any advanced or metastatic solid tumor harboring a KRAS G12D mutation * 1L therapy in combination with carboplatin, pembrolizumab, and pemetrexed in participants with previously untreated metastatic NSCLC * 2L+ therapy in combination with gemcitabine and nab-paclitaxel in participants with metastatic PDAC * 1L therapy in combination with gemcitabine in participants aged 75 years or older with previously untreated metastatic PDAC. Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, DLTs, and dose interruptions/reductions. - Part C: To identify a recommended dose for subsequent studies of combination dosed VS-7375. — Cycle 1 (each cycle is 21 or 28 days)
To identify a recommended dose for subsequent studies of combination dosed VS-7375. Proportion/number of participants with DLTs during the DLT assessment period (through end of Cycle 1). - Part D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part C — Up to 2.5 years
To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part C as: * 2L+ therapy in combination with cetuximab in participants with metastatic colorectal adenocarcinoma * 1L therapy in combination with carboplatin, pembrolizumab, and pemetrexed in participants with previously untreated metastatic NSCLC * 2L+ therapy in combination with gemcitabine and nab-paclitaxel in participants with metastatic PDAC * 1L therapy in combination with gemcitabine in participants aged 75 years or older with previously untreated metastatic PDAC. Confirmed ORR, PFS rate, unconfirmed PR and CR rates, DCR, DOR, and PFS per RECIST v1.1. Overall survival
Trial sites (14)
| Facility | City | Region | Status |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | Recruiting |
| Johns Hopkins University | Baltimore | Maryland | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | Recruiting |
| University of Michigan | Ann Arbor | Michigan | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | Recruiting |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone | New York | New York | Recruiting |
| Univ of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | Recruiting |
| Huntsman Cancer Institute | Salt Lake City | Utah | Recruiting |
| University of Virginia | Charlottesville | Virginia | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | Recruiting |
| Virginia Mason Medical Center | Seattle | Washington | Recruiting |
| Peninsula and Southeast Oncology | Frankston | Victoria | Recruiting |
More Verastem, Inc. trials in Australia
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07020221 on ClinicalTrials.gov ↗ ← All trials in Australia